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Heparin-Induced Thrombocytopenia (HIT) is an adverse drug reaction induced by treatment 
with heparin, which occurs more likely with unfractionated heparin (UFH) than with low-molecular-
weight heparin (LMWH) [1]. HIT has been categorized into two groups; HIT type 1 is defined as a 
mild reaction, non-immune mediated. No complications are seen, and the thrombocytopenia will 
show spontaneous remission whilst continued treatment with heparin. HIT type 2 is an immune-
mediated reaction [2]. Usually, the platelet 4 factor (PF4) is stored in and released from the alpha 
granules of activated platelets. PF4 binds to heparin due to high affinity, and this might trigger 
the formation of immunoglobulin G (IgG) antibodies. HIT occurs only if IgG is attached to the 
heparin-PF4 complex and this binds to platelet receptors. This leads to both a critical prothrombotic 
situation and bleedings caused by thrombocytopenia [3,4]. Type 2 HIT usually inserts 5-14 days 
after the first dose of heparin.
However, one single dose of heparin may cause the development of antibodies, and re-exposure 
to heparin within 3 months may cause serious life-threatening reactions [5,6].
Platelet count <150×109/L defines thrombocytopenia, while severe thrombocytopenia is 
defined by count <50×109/L. Consequences can be life-threatening with a very high mortality rate 
(30%) [7,8], caused by bleedings (thrombocytopenia) and a hypercoagulable state, where most 
patients developed severe thromboembolic complications. Today there are no evidence-based 
recommendations how to treat these patients [9]. The new oral anticoagulants (NOACs) have 
shown relevant properties for the management of HIT, by rapid onset of action, oral administration, 
ease of use and lack of monitoring [10].
Case Report
A 67-year-old white female patient presented to emergency department with dehydration 
and a medical history of a right total knee arthroplasty 8 days before arrival. No clear symptoms 
other than loss of appetite. The patient was hemodynamically stable, which included normal blood 
pressure and pulse. Routine admission laboratory for general medical patients showed increased 
C-Reactive Protein (CRP) level at 190 mg/L [<10 mg/L] and a low haemoglobin level at 5.4 mmol/L 
[7,3 - 9,5 mmol/L]. She started treatment with 4 g piperacillin combined with 0.5 g tazobactam on 
the suspicion of pneumonia.
Due to the high risk of developing thrombosis by being bedridden and the suspicion of pulmonary 
embolism, the patient was treated with Dalteparin 200IU/kg of body weight (Figure 1). Computed 
Tomography (CT) scan of the chest verifies bilateral infiltrates and pulmonary embolism was 
disconfirmed, so the patient was treated for pneumonia with intravenous 4 g Piperacillin combined 
with 0.5 g Tazobactam in 11 days and 500 mg Clarithromycin in 7 days, and then discharged from 
the hospital.
5 days later the patient developed dyspnea, and due to d-dimer 20 L [<0.7] (Table 1) and chest 
CT verified bilateral massive pulmonary embolisms, treatment with Dalteparin 200IU/kg of body 
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This case report illustrates a patient with Heparin-Induced Thrombocytopenia (HIT) who was successfully 
treated with Apixaban. HIT is an adverse drug reaction induced by treatment with heparin. The optimal 
anticoagulation strategy remains uncertain. This case presents a patient who developed massive pulmonary 
embolisms post total knee replacement, she was then treated with low-molecular-weight heparin (LMWH), which 
lead to bleeding and a critically platelet count drop, indicating serious HIT 2 syndrome. 
By discontinuation of LMWH and switch to Apixaban in a modified dose regime, we managed to stop the 
life-threatening complications of LMWH. The platelet count recovered, and the patient survived.
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weight was immediately effectuated (Figure 1). Ultrasound of lower 
extremities and the pelvis were without thromboses.
12 hours later we observed gingival bleeding, petechiae on lower 
extremities and ecchymoses on the truncus. Platelet count showed a 
decrease of 88.9% (from 170×109/L to 20×109/L).
Dalteparin was then immediately discontinued and due to 
bleeding and thrombocytopenia transfusion of platelet concentrate 
was given, which aggravate the patient’s situation. As a result of 
more bleeding and periphery embolies, we observed a further drop in 
platelet count (16×109/L).
As blood test analysis for antibodies directed against PF4 was not 
locally available, the diagnosis of HIT 2 was based on the available 
blood tests (Table 1) and the 4T score (Table 2).
To verify the diagnosis, a blood test was later taken and sent 
abroad, but unfortunately it went missing.
At this point, the patient was in a life-threatening situation 
with bleedings caused by thrombocytopenia and with severe 
thromboembolic complications caused by a hypercoagulable state. To 
turn this situation, we started with a single dose of Apixaban 2.5mg.
We then observed increasing platelet count, and thereafter 
a modified regime was used to treat the patient, that consisted 
of Apixaban 2.5 mg BID, then Apixaban 5.0 mg BID and then a 
treatment dose of Apixaban 10.0 mg BID 1 week. During the next 7 
days, the platelet count increased to 190×109/L, and the patient was 
asymptomatic. Figure 1 illustrates the increase in platelets during 
Apixaban treatment, in the same period we observed a decrease in 
fibrinogen and APTT and d-dimer (Table 1). 
4Ts score was used to investigate if the patient were likely to 
have HIT, by assessing the probability of having HIT. Score result 
>4 represents a high probability of HIT and can be divided into 
intermediate and high risk. The variables include thrombocytopenia, 
timing, thrombosis and the likelihood of another diagnosis. In our 
case, the patient scored 7 points (Table 1), as a result of the decrease 
in platelet count of 89%, timing <4 days after exposure, bilateral PE 
and no other obvious reasons. 
Figure 1: The trend of thrombocytopenia in the patient.
Table 1: Laboratory test results after heparin exposure.
Laboratory test Day 30 Day 31 Day 32 Day 33 Day 34 Day 35 Day 36 Day 37 Day 38
Hemoglobin (mmol/L) 6,50 6,40 5,60 6,20 6,50 6,40
Platelet Count (>150×109/L) 170,00 19,00 16,00 21,00 29,00 58,00 84,00 136,00 190,00
Fragment D-dimer 20,00 5,80 4,90 3,70 7,30 6,00
Fibrinogen (5-11.5µmol/L) 22,70 21,50 16,90 16,70 14,80
APTT (27-40 sec) 68,00 56,00 37,00
INR (0.8-1.2) 1,40 1,40 1,50 1,60 1,70 1,50
Antithrombin(0.8-1.2 ×103 IU/L) 0,61 0,78 0,82 0,84 0,84
Table 2: 4Ts Score of the patient.
Variable Score
Thrombocytopenia 2
Timing of platelet count decrease 1
Thrombosis or other sequelae 2
Other causes of thrombocytopenia 2
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2 points were given if the patient had a >50% platelet count 
decrease, decrease in 5-10 days, proven new thrombosis and no 
other explanation for platelet count decrease. 1 point was given if 
the patient had a 30-50% platelet count decrease, consistent with 
5-10 days/decrease <1 day with lately heparin exposure, progressive/
recurrent thrombosis and possibly no other evident cause. Lastly, 1 
point was given, if the patient had <30 % platelet count decrease, a 
decrease in less than 5 days (with no recent heparin exposure), none 
thrombosis nor other present cause [11].
Discussion
HIT can occur in 5% of patients exposed to heparin, it is an 
extremely severe condition with a high mortality rate. Usually, HIT 
occurs in patients treated with UFH; however, in this case report the 
patient was exposed to LMWH. Interestingly in this case, the patient 
before developing pulmonary embolism was treated with one single 
dose of LMWH due to the high risk of developing thrombosis by being 
bedridden and suspicion of pulmonary embolism. Subsequently, the 
platelet count actually increases from 251×109/L to 423×109/L.
This single dose of LMWH might have caused the development 
of antibodies that remained in the patient and caused both the 
extreme hypercoagulable state and the extreme drop in platelets 
(20×109/L) when the patient shortly after was exposed to heparin due 
to life-threatening pulmonary embolism. Whether the pulmonary 
embolism was due to the already existing antibodies which caused 
a prothrombotic state remains unclear. But consequently, just 
a few hours after retreatment with heparin 28/2 due to massive 
pulmonary embolisms, the patient developed a life-threatening 
thrombocytopenia and a prothrombotic state which in this case lead 
to a severe health state with pulmonary and periphery embolisms, 
which usually ends fatally in 30% of the patients. 
There are no existing guidelines on how to manage this critical 
condition, to our knowledge, and only a few case reports have 
previously been published. 
In our case we successfully used a modified regime that consisted 
of Apixaban 2.5 mg BID for 1 day, then Apixaban 5.0 mg BID and 
then a treatment dose of Apixaban 10.0 mg BID for 1 week in order 
to restore the haemostatic balance. Treatment of HIT mainly consists 
in discontinuing heparin treatment and switching to an alternative 
anticoagulant, which could be direct thrombin inhibitors or direct 
factor, Xa inhibitors. Treatment with warfarin and thrombocyte 
transfusions is contraindicated as the risk of thrombosis increases 
[9]. Apixaban was used in this case for anticoagulation management 
as the HIT antibodies do not target the drug [12].
This treatment regime is supported by a few other case reports 
in which describes the beneficial effect of NOACs in the treatment of 
HIT syndrome [13,14]. 
Conclusion
Heparin treatment among others has potential to induce 
thrombocytopenia in patients. This case report suggests attention to 
platelet counts in patients treated with LMWH as well as a careful 
clinical examination of the patient can be crucial for the best 
prognosis.
In this case, the patient is treated first with one single dose of 
LMWH as prophylaxis, and then gets exposed with LMWH again 
due to pulmonary embolism, which causes the development of a 
fulminant immune-mediated HIT reaction. Our patient had an 
extensive clot burden and a critical platelet drop. Data in treatment 
of these patients are very limited. However, our modified treatment 
with Apixaban, we managed to turn this fierce reaction and critical 
situation, and the recovered patient is now dismissed from the 
hospital with a continued treatment with Apixaban 5 mg BID for at 
least 6 months. 
This case enlightens the need for a worldwide data collection 
for this type of patient in order to make international treatment 
guidelines for HIT 2 patients. 
This case report demonstrates that Apixaban can be used as a safe 
treatment option in patients with HIT. 
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